Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Imlunestrant Tosylate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Imlunestrant Tosylate is a Small molecule drug targeting ER, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Elacestrant hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Elacestrant hydrochloride is a Small molecule drug targeting ERα, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Repotrectinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Repotrectinib is a Small molecule drug targeting ROS1 x TrkA x TrkB x TrkC, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks.
Latest Hotspot
8 min read
Futibatinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Futibatinib is a Small molecule drug targeting FGFR1 x FGFR2 x FGFR3 x FGFR4, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks.
Latest Hotspot
8 min read
Tozorakimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Tozorakimab is a Monoclonal antibody targeting IL-33, at NDA/BLA. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Belapectin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Belapectin is a Polymer targeting galectin-3, at Phase 2. This 2026 report reviews clinical evidence, IP, deals, risks and a CONDITIONAL GO view.
Latest Hotspot
8 min read
Aldafermin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Aldafermin: Discontinued. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Fordadistrogene movaparvovec Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Fordadistrogene movaparvovec is a AAV based gene therapy targeting DAG1, at Discontinued. This 2026 report reviews clinical evidence, IP, deals, risks.
Latest Hotspot
8 min read
Valoctocogene roxaparvovec Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Valoctocogene roxaparvovec: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Garadacimab-gxii Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Garadacimab-gxii is a Monoclonal antibody targeting Factor XIIa, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Clopidogrel napadisilate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Clopidogrel napadisilate is a Small molecule drug targeting P2Y12 receptor, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks.
Latest Hotspot
8 min read
Datopotamab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Datopotamab is a Monoclonal antibody targeting Trop-2, at Clinical. This 2026 report reviews clinical evidence, IP, deals, risks and a HOLD / OPTION view.